Your session is about to expire
← Back to Search
Rogaratinib for Sarcoma and Gastrointestinal Stromal Tumors
Study Summary
This trial studies the effect of rogaratinib in treating patients with sarcoma with a change in FGFRs or SDH-deficient GIST. Rogaratinib may stop growth of tumor cells by blocking enzymes needed for cell growth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My sarcoma has an FGFR alteration, is advanced or has spread, and cannot be removed by surgery.I am 18 years old or older.You are not currently taking any experimental drugs or treatments.I am not taking any medications that affect my heart's electrical cycle.My calcium and phosphate levels are normal.I have been cancer-free for over 5 years, except for certain skin cancers or cervical pre-cancer.I can take care of myself but might not be able to do heavy physical work.I had hepatitis C but am cured, or I'm being treated with no detectable virus.I am allergic to medications similar to rogaratinib.My heart function is classified as class 2B or better, despite my history of heart issues or treatments.I am not pregnant and have had a negative pregnancy test recently.I finished my cancer treatment more than 2 weeks ago, or 6 weeks ago for specific drugs.I am HIV positive, on treatment that doesn't interact with CYP3A4, and my viral load has been undetectable for 6 months.I am not taking any drugs that strongly affect how my body processes certain medications.I agree to use effective birth control during and for 4 months after the study.My hepatitis B virus load is undetectable with treatment.My brain scans show no worsening after treatment for brain metastases.I can understand and am willing to sign the consent form, or I have someone who can do it for me.I am not pregnant or breastfeeding.I have recovered from side effects of previous cancer treatments, except for hair loss.My cancer has worsened after one standard chemotherapy treatment.
- Group 1: Treatment (rogaratinib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there numerous locations where this experiment is being conducted within the city limits?
"Currently, this clinical trial is taking place in 17 different locations. They are situated in cities such as Chicago, Irvine and Saint Louis. To cut down on commute times and travel costs, patients are encouraged to select the location nearest them."
Could you give me the total number of people who have signed up for this clinical trial?
"This study requires 48 individuals that meet the specified inclusion criteria. Those interested in participating can do so at Northwestern University located in Chicago, Illinois or City of Hope at Irvine Lennar which is situated in Irvine, California."
What is the margin of error for Rogaratinib?
"While there is some data supporting Rogaratinib's safety, it remains unproven in terms of efficacy and thus received a score of 2."
What does the scientific community know about Rogaratinib from past research?
"There are 4 ongoing clinical trials researching the effects of Rogaratinib. None of these active studies are in Phase 3, which is concerning as this would typically be where more definitive results would be found. The majority of these studies originate from Bethesda, Maryland; however, there are a total of 93 locations running similar research projects."
Are we still taking people for this research project?
"The information available on clinicaltrials.gov does show that this study is still recruiting patients. The trial was announced on February 1st, 2021 and the most recent update was November 8th, 2022. Between 17 different hospitals or clinics, a total of 48 people are needed for the study."
Share this study with friends
Copy Link
Messenger